Triple therapy shows promise in shrinking sarcomas before surgery

This study tests whether combining an immunotherapy drug (pembrolizumab) with another immune-boosting protein (eftilagimod alpha) and radiation therapy can shrink soft tissue sarcomas before surgery. About 40 adults with high-risk, non-spread sarcomas will receive this combination, then have their tumor removed to see how much of it has been destroyed. The goal is to improve outcomes, but ongoing monitoring and potential long-term treatment may still be needed.